Back to results
US 2024/0199577 A1Published application
Acoramidis analogs for stabilizing transthyretin and inhibiting transthyretin misfolding
AssigneeProtego Biopharma, Inc.
InventorsRichard F. Labaudiniere, Bradley Dean Tait
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds having activity against TTR related conditions, and pharmaceutically accepted salts and solvates thereof. Also provided are methods of using the compounds for inhibiting and preventing TTR aggregation and/or amyloid formation in the peripheral nerves, kidney, cardiac tissue, eye and CNS, and of treating a subject with peripheral TTR amyloidosis.
Claims7
A compound having the structure of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- A is
- X1 is O, S or NR6;
- X2 is a bond, O, S, NR6, N+R6R7 or P+(Ar)2;
- X3 is O, S or NR6;
- n is an integer from 0-6;
- m is an integer from 0-6;
- Ar is aryl, heteroaryl or heteroarylium, all optionally substituted;
- R1, R2, R3, R4, R5, R6 and R7 are each independently H, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl or heteroaralkyl, all optionally substituted, or OH, OR8, COR9, —(CR10R11)mX3R8 or —(CR10R11)mX3COR9;
- R8 and R9 are each independently H, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl or heteroaralkyl, all optionally substituted;
- or R8 is selected as above and R9 is
- R10 and R11 are each independently H, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl or heteroaralkyl, all optionally substituted, or OH or OR8;
- or R1-R2 form a cycloalkyl or heterocycloalkyl;
- and R3-R11 are selected as above;
- or R3-R4 form a cycloalkyl or heterocycloalkyl;
- and R1, R2 and R5-R11 are selected as above;
- or R10-R11 form a cycloalkyl or heterocycloalkyl;
- and R1-R9 are selected as above;
- or R1-R3 form a bond, —(CR10R11)m— or —(CR10═CR11)m—;
- and R2 and R4-R11 are selected as above;
- or R2-R4 form a bond, —(CR10R11)m— or —(CR10═CR11)m—;
- and R1, R3 and R5-R11 are selected as above;
- or R1-R5 form a bond, —(CR10R11)m— or —(CR10═CR11)m—;
- and R2 -R4 and R6-R11 are selected as above;
- or R2-R6 form a bond, —(CR10R11)m— or —(CR10═CR11)m—;
- and R1, R3-R5 and R7-R11 are selected as above;
- or R3-R5 form a bond, —(CR10R11)m—, —(CR10═CR11)m— or —[C(R10)═C(R11)—CO]—;
- and R1, R2, R4 and R6-R11 are selected as above;
- or R4-R6 form a bond, —(CR10R11)m— or —(CR10═CR11)m—;
- and R1-R3, R5 and R7-R11 are selected as above;
- or R5-R6 form —(CR10R11)m— or —(CR10R11)m—X3—(CR10R11)m—;
- and R1-R4 and R7-R11 are selected as above;
- with the provisos that:
- when X1 is oxygen, X2 is a bond, and R1, R2 and R5 are H, then n is not 0;
- and
- when X1 is NH, X2 is a bond, and R1, R2, R3, R4 and R5 are H, then n is not 1.
33 more elements
A compound having the structure of Formula (II):
- or a pharmaceutically acceptable salt thereof, wherein:
- A is
- X1 O, S or NR6;
- X2 is a bond, O, S, NR6, N+R6R7 or P+(Ar)2;
- X3 is O, S or NR6;
- n is an integer from 0-6;
- m is an integer from 0-6;
- Ar is aryl, heteroaryl or heteroarylium, all optionally substituted;
- R1, R2, R3, R4, R5, R6 and R7 are each independently H, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl or heteroaralkyl, all optionally substituted, or OH, OR8, COR9, —(CR10R11)mX3R8 or —(CR10R11)mX3COR9;
- R8 and R9 are each independently H, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl or heteroaralkyl, all optionally substituted;
- or R8 is selected as above and R9 is
- R10 and R11 are each independently H, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl or heteroaralkyl, all optionally substituted, or OH or OR8;
- or R1-R2 form a cycloalkyl or heterocycloalkyl;
- and R3-R11 are selected as above;
- or R3-R4 form a cycloalkyl or heterocycloalkyl;
- and R1, R2 and R5-R11 are selected as above;
- or R10-R11 form a cycloalkyl or heterocycloalkyl;
- and R1-R9 are selected as above;
- or R1-R3 form a bond, —(CR10R11)m— or —(CR10═CR11)m—;
- and R2 and R4-R11 are selected as above;
- or R2-R4 form a bond, —(CR10R11)m— or —(CR10═CR11)m—;
- and R1, R3 and R5-R11 are selected as above;
- or R1-R5 form a bond, —(CR10R11)m— or —(CR10═CR11)m—;
- and R2-R4 and R6-R11 are selected as above;
- or R2-R6 form a bond, —(CR10R11)m— or —(CR10═CR11)m—;
- and R1, R3-R5 and R7-R11 are selected as above;
- or R3-R5 form a bond, —(CR10R11)m—, —(CR10═CR11)m— or —[C(R10)═C(R11)—CO]—;
- and R1, R2, R4 and R6-R11 are selected as above;
- or R4-R6 form a bond, —(CR10R11)m— or —(CR10═CR11)m—;
- and R1-R3, R5 and R7-R11 are selected as above;
- or R5-R6 form —(CR10R11)m— or —(CR10R11)m—X3—(CR10R11)m—;
- and R1-R4 and R7-R11 are selected as above.
29 more elements
The compound having one of the following structures:
Dependencies are inferred from the claim text.